Seminoma Clinical Trials

10 recruiting

Seminoma Trials at a Glance

16 actively recruiting trials for seminoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Not Applicable with 6 trials, with the heaviest enrollment activity in Aurora, Bardstown, and Ankeny. Lead sponsors running seminoma studies include Heinrich-Heine University, Duesseldorf, Children's Oncology Group, and Centre Oscar Lambret.

Browse seminoma trials by phase

Treatments under study

About Seminoma Clinical Trials

Looking for clinical trials for Seminoma? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Seminoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Seminoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Hearing LossMetastatic Malignant Germ Cell TumorMetastatic Malignant Nongerminomatous Germ Cell Tumor+4 more
City of Hope Medical Center44 enrolled1 locationNCT07218913
Recruiting
Phase 3

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Germ Cell TumorChildhood Extracranial Germ Cell TumorExtragonadal Embryonal Carcinoma+27 more
Children's Oncology Group1,780 enrolled630 locationsNCT03067181
Recruiting
Not Applicable

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting
Not Applicable

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Quality of LifeTesticular CancerSeminoma+2 more
Sahlgrenska University Hospital160 enrolled1 locationNCT07498959
Recruiting
Phase 2

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

Carcinoma, Small CellNeuroendocrine TumorsGastrointestinal Stromal Tumors+11 more
Centre Oscar Lambret88 enrolled3 locationsNCT05500391
Recruiting

THERApy De-escalation for TESTicular Cancer

Seminoma
Queen Mary University of London30 enrolled1 locationNCT06309745
Recruiting
Not Applicable

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

Lymphadenopathy RetroperitonealStage II Testicular Seminoma
University Health Network, Toronto25 enrolled1 locationNCT05345158
Recruiting
Phase 2

PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

Seminoma
Heinrich-Heine University, Duesseldorf60 enrolled1 locationNCT06144736
Recruiting
Not Applicable

Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer

Germ Cell TumorNonseminomatous Germ Cell TumorSeminoma
Heinrich-Heine University, Duesseldorf44 enrolled1 locationNCT06133543
Recruiting
Not Applicable

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

Urothelial CarcinomaCervical CarcinomaCutaneous Melanoma+7 more
Institut Claudius Regaud450 enrolled1 locationNCT06967961
Recruiting
Phase 2

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

Germ Cell TumorOvarian Germ Cell TumorNon-seminomatous Germ Cell Tumor
Nabil Adra64 enrolled1 locationNCT04804007
Recruiting
Not Applicable

Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma

Seminoma
Tata Memorial Centre74 enrolled2 locationsNCT05142982
Recruiting
Phase 2

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

SeminomaStage II
Centre Leon Berard90 enrolled15 locationsNCT05529251
Recruiting

MicroRNA as Markers in Testicular Cancer

SeminomaTesticular Germ Cell CancerNon-Seminoma Testicular Cancer+5 more
Haukeland University Hospital350 enrolled6 locationsNCT04914026
Recruiting

Identifying and validating predictive and prognostic biomarkers in male Germ Cell Tumours to improve the management and outcomes in both stage 1 and disseminated disease.

Germ Cell Tumour (GCT)Seminoma
Walter and Eliza Hall Institute for Medical Research800 enrolled6 locationsACTRN12618000931279
Recruiting
Phase 2

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

Seminoma
Gustave Roussy, Cancer Campus, Grand Paris271 enrolled1 locationNCT01887340